News

Top-line data support Phase 3 trial of LNK01001 in hard-to-treat AS

An experimental therapy called LNK01001 can safely lower a measure of inflammation, pain, and stiffness in adults with active ankylosing spondylitis (AS) who were refractory or intolerant to non-steroidal anti-inflammatory drugs. These top-line data from a 12-week Phase 2 clinical trial support moving LNK01001 to a Phase 3 trial,…

Contents of cell cargo carriers may offer insights into AS biomarkers

Exosomes, which are tiny carriers for cellular cargo, are found to have significantly different contents in ankylosing spondylitis (AS) patients compared with healthy people, which in turn has marked influences on immune cell function, according to a recent study. Researchers specifically identified that the profile of molecules called microRNAs…

Ankylosing spondylitis genes, potential treatments ID’d: Study

Genes involved in ankylosing spondylitis (AS) as well as potential new therapies have been identified through a computer-based analysis, according to a study. The findings “contribute to our understanding of the molecular mechanisms underlying the onset and progression of AS. They also provide candidate targets for the diagnosis and…

Bone disease blood test may help predict AS radiographic progression

A blood test for bone disease that measures the levels of an enzyme called alkaline phosphatase (ALP) may predict disease progression of ankylosing spondylitis five years before abnormalities can be observed on radiographic exams, according to a new study. “This is not only useful for finding bone-specific biomarkers that…

Fatty lesions don’t explain new bone formation in AS: Study

The effects of inflammation on the later development of new bone outgrowths in certain parts of the spine in ankylosing spondylitis (AS) patients are largely not explained by the intermediate formation of fatty deposits, according to a new study. The findings, which take into account data from two clinical…

Potential AS genetic biomarkers identified in study

Genetic analyses revealed a number of genes with altered activity in ankylosing spondylitis (AS) patients compared with healthy people, which researchers believe could serve as novel disease biomarkers. Among them, the PPARG and MDM2 genes — both of which are involved in inflammation — were found to hold the…